Correlation of platelet aggregation, plasma factor activity, and megathrombocytes in diabetic subjects with an without vascular disease.
Second-phase platelet aggregation induced by adenosine diphosphate (ADP) and epinephrine was measured in fasting platelet-rich plasma in normals, "prediabetics," and diabetics with or without vascular disease. "Plasma factor" potentiation of ADP-induced second-phase platelet aggregation was also estimated, as were megathrombocyte numbers in the same patient groups. There was an increased sensitivity of second-phase platelet aggregation noted with both aggregating agents in all diabetic groups except for the prediabetics. This activity was paralleled by an increase in plasma factor activity. In vivo evidence of an increased turnover of platelets in frank diabetics was suggested by increased numbers of megathrombocytes. These studies demonstrate that platelets from diabetics are sensitive to aggregating agents and that this sensitivity may be related to plasma factor(s) present in diabetics. In vivo platelet aggregation may be present in diabetics. Longitudinal studies will be necessary to establish the relationship of these findings to the genesis of diabetic vascular disease.
D000328:Adult; D001772:Blood Cell Count; D001779:Blood Coagulation Factors / Q000032:analysis*; D001792:Blood Platelets / Q000378:metabolism; D002986:Clinical Trials as Topic; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood*; D003928:Diabetic Nephropathies / Q000097:blood; D003930:Diabetic Retinopathy / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation; D011236:Prediabetic State / Q000097:blood; D014652:Vascular Diseases / Q000209:etiology
D001779:Blood Coagulation Factors